Bristol-Myers Squibb (NYSE:BMY) Shares Sold by John G Ullman & Associates Inc.

John G Ullman & Associates Inc. trimmed its position in shares of Bristol-Myers Squibb (NYSE:BMY) by 7.6% in the first quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund owned 333,232 shares of the biopharmaceutical company’s stock after selling 27,549 shares during the period. Bristol-Myers Squibb makes up about 2.8% of John G Ullman & Associates Inc.’s holdings, making the stock its 6th biggest holding. John G Ullman & Associates Inc.’s holdings in Bristol-Myers Squibb were worth $18,071,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds have also made changes to their positions in the company. Creative Planning raised its position in Bristol-Myers Squibb by 5.3% in the third quarter. Creative Planning now owns 363,032 shares of the biopharmaceutical company’s stock valued at $21,070,000 after purchasing an additional 18,243 shares during the period. Jacobs Levy Equity Management Inc. raised its position in Bristol-Myers Squibb by 20.5% in the third quarter. Jacobs Levy Equity Management Inc. now owns 645,662 shares of the biopharmaceutical company’s stock valued at $37,474,000 after purchasing an additional 109,676 shares during the period. Diversified Trust Co raised its position in Bristol-Myers Squibb by 1.2% in the third quarter. Diversified Trust Co now owns 47,382 shares of the biopharmaceutical company’s stock valued at $2,750,000 after purchasing an additional 580 shares during the period. Comerica Bank increased its position in shares of Bristol-Myers Squibb by 96.1% during the third quarter. Comerica Bank now owns 748,822 shares of the biopharmaceutical company’s stock worth $43,462,000 after acquiring an additional 367,044 shares during the last quarter. Finally, Allen Mooney & Barnes Investment Advisors LLC purchased a new stake in shares of Bristol-Myers Squibb during the third quarter worth about $2,141,000. 76.41% of the stock is currently owned by institutional investors and hedge funds.

Analyst Ratings Changes

A number of analysts have recently issued reports on BMY shares. BMO Capital Markets dropped their target price on Bristol-Myers Squibb from $55.00 to $48.00 and set a “market perform” rating on the stock in a research report on Friday, April 26th. Wells Fargo & Company lifted their target price on Bristol-Myers Squibb from $51.00 to $52.00 and gave the stock an “equal weight” rating in a research report on Thursday, April 18th. William Blair reaffirmed a “market perform” rating on shares of Bristol-Myers Squibb in a research report on Monday, April 1st. Barclays decreased their price target on Bristol-Myers Squibb from $43.00 to $41.00 and set an “equal weight” rating for the company in a research note on Wednesday. Finally, StockNews.com downgraded Bristol-Myers Squibb from a “strong-buy” rating to a “buy” rating in a research note on Thursday, June 27th. One equities research analyst has rated the stock with a sell rating, thirteen have given a hold rating and four have given a buy rating to the company. According to data from MarketBeat.com, the stock presently has a consensus rating of “Hold” and a consensus target price of $59.50.

Bristol-Myers Squibb Price Performance

NYSE:BMY traded down $0.38 during midday trading on Thursday, hitting $40.75. 17,883,034 shares of the stock were exchanged, compared to its average volume of 15,683,951. Bristol-Myers Squibb has a one year low of $39.35 and a one year high of $65.38. The company has a market capitalization of $82.59 billion, a price-to-earnings ratio of -13.14, a P/E/G ratio of 13.68 and a beta of 0.44. The business has a 50-day moving average price of $41.99 and a two-hundred day moving average price of $47.47. The company has a current ratio of 1.11, a quick ratio of 0.99 and a debt-to-equity ratio of 2.99.

Bristol-Myers Squibb (NYSE:BMY) last announced its earnings results on Thursday, April 25th. The biopharmaceutical company reported ($4.40) EPS for the quarter, topping the consensus estimate of ($4.53) by $0.13. Bristol-Myers Squibb had a positive return on equity of 8.83% and a negative net margin of 13.50%. The firm had revenue of $11.87 billion for the quarter, compared to analysts’ expectations of $11.45 billion. During the same quarter in the previous year, the company earned $2.05 earnings per share. The firm’s quarterly revenue was up 4.7% compared to the same quarter last year. Sell-side analysts predict that Bristol-Myers Squibb will post 0.58 EPS for the current year.

Bristol-Myers Squibb Dividend Announcement

The company also recently announced a quarterly dividend, which will be paid on Thursday, August 1st. Investors of record on Friday, July 5th will be issued a dividend of $0.60 per share. The ex-dividend date is Friday, July 5th. This represents a $2.40 annualized dividend and a yield of 5.89%. Bristol-Myers Squibb’s payout ratio is -77.42%.

Bristol-Myers Squibb Company Profile

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, and neuroscience diseases. The company's products include Eliquis for reduction in risk of stroke/systemic embolism in non-valvular atrial fibrillation, and for the treatment of DVT/PE; Opdivo for various anti-cancer indications, including bladder, blood, CRC, head and neck, RCC, HCC, lung, melanoma, MPM, stomach and esophageal cancer; Pomalyst/Imnovid for multiple myeloma; Orencia for active rheumatoid arthritis and psoriatic arthritis; and Sprycel for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia.